Guggenheim lowered the firm’s price target on Exact Sciences to $73 from $90 and keeps a Buy rating on the shares. The firm is applying a peer group median multiple on its 2025 revenue estimate given Shield could be FDA-approved with a broader label and the revenue ramp is slower than the firm anticipated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences Refines Teams, Projects Growth Amid Leadership Changes
- Illumina appoints Cunningham as Chief Commercial Officer
- Exact Sciences assumed with a Buy at Jefferies
- Craig-Hallum would be buyers of Exact Sciences amid weakness
- Exact Sciences to present new data on screening and diagnostic portfolio at ASCO